YL413 / MediLink - LARVOL DELTA

YL413: A novel dual-payload anti-HER2 antibody-drug conjugate demonstrating potent preclinical activity (AACR 2026) - "Trastuzumab, topoisomerase I inhibitors, and microtubule inhibitors were expected to demonstrate anti-tumor activity in clinical trials. The dual-payload HER2 ADC exhibited strong anti-tumor activity in vitro and in vivo, indicating potential to overcome Enhertu® resistance. YL413 retains Topo1 inhibitor efficacy, supplemented by a microtubule inhibitor, with possible use in earlier treatment lines."

ADC • Preclinical • Oncology

An innovative dual-payload ADC combining topoisomerase 1 inhibitor and a tubulin inhibitor efficiently overcomes drug resistance (AACR 2025) - "ADC characterization showed good stability, homogeneity and precise DAR values for the conjugation of both payload-linkers to Trastuzumab. In summary, we developed dual-payload ADCs with intention for resolving topo1 inhibitor induced tumor resistance issues. The dual-payload Her2 ADC demonstrated potent in vitro and in vivo anti-tumor activities, showing the potential to overcome the multidrug resistant mechanism and Enhertu resistance."

Oncology • ABCB1 • ABCG2 • HER-2